Proteomics study on paclitaxel-resistant ovarian cancer subline

Abstract

Abstract: AIM: To assess the differential protein expression profiles of paclitaxel-resistant ovarian cancer sub-line and ovarian cancer cell line in order to detect the proteins associated with paclitaxel-resistance evolution.METHODS: The epithelial ovarian cancer cell line SKOV3 and its paclitaxel-resistant sub-line SKOV3-TR30 were selected. Total proteins from the two cell lines were separated by 2-DE and the differentially expressed proteins were identified by mass spectrometry. Then three protein (Sorcin,Cathepsin B,HSP27) expressions in paclitaxel- resistant cells were compared with parental cell line by Westerrn blot analysis and immunocytochemistry.RESULTS: (1) Twenty-three proteins spots showed significant changes in SKOV3-TR30 compared to SKOV3. Among them, sixteen proteins were found to be up-regulated and seven proteins were down-regulated in chemoresistant cells (expression regulation more than 3-fold). (2) Seven of these proteins were identified by tandem mass spectrometry as follows: sorcin,cathepsin B precursor,calponin-3,heat-shock protein 27,vimentin,nicotinate-nucleotide pyrophosphoylase,and hemoglobin beta chain. (3) Western-blot analysis indicated that sorcin, cathepsin B and HSP27 were up-regulated in SKOV3-TR30. Immunocytochemistry revealed that the three proteins were all located in cytoplasm, especially perinudear.CONCLUSION: The expression of signal transducing molecules associated with cytoskeleton were moderately up-regulated in paclitaxel-resistant ovarian cancer subline. These proteins may provide new targets for therapy, but their role in drug resistance in ovarian cancer, especially in vivo need a further study.

Key words: ovarian cancer, paclitaxel, chemoresistance, proteomic, cytoskeleton

CLC Number:

R737.31

FU Jun, YE Da-feng, FU Yun-feng. Proteomics study on paclitaxel-resistant ovarian cancer subline[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 525-530.

References

[1] Gradishar WJ.Taxanes for the treatment of metastatic breast cancer[J]. Breast Cancer (Auckl), 2012, 6:159-171.
[2] Jiang J, Liang X, Zhou X, et al.Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials[J]. Int J Clin Oncol,2013,18(6):1005-1013.
[3] Glaze S, Teitelbaum L, Chu P, et al.Dose-dense Paclitaxel with Carboplatin for advanced ovarian cancer: a feasible treatment alternative[J]. J Obstet Gynaecol Can, 2013, 35(1):61-67.
[4] Lu B,Sun L,Yan X,et al.Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer[J].Med Oncol,2015,32(1):345.
[5] 彭晔,王美芹,谢娜,等.紫杉醇+顺铂方案联合沙利度胺治疗晚期非小细胞肺癌的临床研究[J].中国临床药理学与治疗学,2013,18(3):317-321.
[6] Hida K, Akiyama K, Ohga N, et al.Tumour endothelial cells acquire drug resistance in a tumour microenvironment[J]. J Biochem,2013, 153(3):243-249.
[7] Tian Y, Tan AC, Sun X, et al. Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance[J]. Proteomics Clin Appl,2009, 3(11):1288-1295.
[8] Zhu H, Snyder M.Protein arrays and microarrays[J]. Curr Opin Chem Biol,2001, 5(1):40-45.
[9] Issaq HJ, Veenstra TD, Conrads TP, et al.The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification[J]. Biochem Biophys Res Commun,2002, 292(3):587-592.
[10]Fields S, Song O.A novel genetic system to detect protein-protein interactions[J]. Nature,1989, 340(6230):245-246.
[11]Antin PB, Forry-Schaudies S, Friedman TM, et al.Taxol induces postmitotic myoblasts to assemble interdigitating microtubule-myosin arrays that exclude actin filaments[J]. J Cell Biol ,1981,90(2):300-308.
[12]Salmon ED, Wolniak SM.Taxol stabilization of mitotic spindle microtubules: analysis using calcium-induced depolymerization[J]. Cell Motil,1984, 4(3):155-167.
[13]Lokuta AJ, Meyers MB, Sander PR, et al. Modulation of cardiac ryanodine receptors by sorcin[J]. J Biol Chem,1997, 272(40):25333-25338.
[14]Schliwa M, Euteneuer U, Bulinski JC,et al.Calcium lability of cytoplasmic microtubules and its modulation by microtubule-associated proteins[J]. Proc Natl Acad Sci USA,1981, 78(2):1037-1041.
[15]Yamaqishi N,Nakao R,Kondo R,et al.Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein[J].Biochem Biophys Res Commun,2014,448(4):430-436.
[16]Liu X,Chen L,Feng B,et al.Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma[J].Anat Rec(Hoboken),2014,297(2):215-221.
[17]Colotti G,Poser E,Fiorillo A,et al.Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells[J].Molecules,2014,19(9):13976-13989.
[18]Gondi CS, Rao JS.Cathepsin B as a cancer target[J]. Expert Opin Ther Targets,2013, 17(3):281-291.
[19]Watson CJ, Kreuzaler PA.The role of cathepsins in involution and breast cancer[J]. J Mammary Gland Biol Neoplasia,2009, 14(2):171-179.
[20]Hino M, Kurogi K, Okubo MA, et al.Small heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa cells[J]. Biochem Biophys Res Commun,2000, 271(1):164-169.
[21]Bukhari S, Mokhdomi TA, Chikan NA, et al. Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: insights from serological screening and computational modelling[J].Mol Biosyst,2015,11(1):159-169.
[22]Fu CH, Lin RJ, Yu J, et al.A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation[J].Stem Cells,2014,32(8):2048-2060.
[23]Chu JJ, Chen KD, Lin YL,et al.Taxol induces concomitant hyperphosphorylation and reorganization of vimentin intermediate filaments in 9L rat brain tumor cells[J].J Cell Biochem,1998,68(4):472-483.
[24]Yuasa T, Yano R, Izawa T, et al. Calponin expression in renal tubulointerstitial fibrosis induced in rats by Cisplatin[J].J Toxicol Pathol,2014,27(1):97-103.